Skip to main content
. 2022 Feb 16;13:821689. doi: 10.3389/fendo.2022.821689

Table 1.

Baseline characteristics of 1,587,962 participants stratified by MAFLD and hyperuricemia in the sectional study.

Overall(n=1,587,962) Non-MAFLD(n=951,985) MAFLD(n=635,977) P-value* Non-hyperuricemia(n=1,369,166) Hyperuricemia(n=218,796) P-value*
Age, median (IQR) years 46.00 [36.00, 55.00] 44.00 [34.00, 54.00] 48.00 [39.00, 56.00] <0.001 46.00 [36.00, 55.00] 44.00 [35.00, 54.00] <0.001
Male sex, n(%) 958184 (60.34) 496056 (52.11) 462128(72.66) <0.001 767337(56.04) 190847(87.23) <0.001
FBG (mmol/L, median (IQR)) 5.16 [4.79, 5.60] 5.04 [4.70, 5.40] 5.40 [4.97, 5.98] <0.001 5.14 [4.78, 5.60] 5.25 [4.85, 5.73] <0.001
LDL-C (mmol/L, median (IQR)) 2.72 [2.21, 3.28] 2.60 [2.12, 3.14] 2.91 [2.38, 3.46] <0.001 2.70 [2.20, 3.26] 2.84 [2.31, 3.39] <0.001
HDL-C (mmol/L, median (IQR)) 1.30 [1.10, 1.55] 1.40 [1.18, 1.65] 1.16 [1.00, 1.36] <0.001 1.33 [1.12, 1.58] 1.14 [0.98, 1.33] <0.001
TC (mmol/L, median (IQR)) 4.72 [4.14, 5.35] 4.58 [4.04, 5.19] 4.93 [4.34, 5.57] <0.001 4.69 [4.12, 5.32] 4.92 [4.33, 5.56] <0.001
TG (mmol/L, median (IQR)) 1.31 [0.89, 1.99] 1.05 [0.76, 1.51] 1.83 [1.30, 2.65] <0.001 1.24 [0.85, 1.85] 1.92 [1.31, 2.86] <0.001
WC (cm, median (IQR)) 83.00 [75.00, 90.00] 78.00 [71.00, 84.00] 91.00 [86.00, 96.00] <0.001 82.00 [74.00, 89.00] 90.00 [84.00, 96.00] <0.001
BMI (kg/m2, median (IQR)) 24.53 [22.43, 26.69] 23.20 [21.09, 24.96] 26.51 [24.87, 28.40] <0.001 24.25 [22.10, 26.37] 26.17 [24.32, 28.28] <0.001
ALT (U/L, median (IQR)) 21.00 [15.00, 31.00] 18.00 [13.00, 25.00] 27.90 [19.64, 40.00] <0.001 20.00 [14.00, 29.00] 29.00 [20.00, 42.10] <0.001
AST (U/L, median (IQR)) 21.40 [17.70, 26.40] 20.30 [17.00, 25.00] 23.00 [19.00, 29.00] <0.001 21.00 [17.00, 26.00] 24.00 [20.00, 31.00] <0.001
BUN (mmol/L, median (IQR)) 4.63 [3.87, 5.51] 4.51 [3.76, 5.40] 4.80 [4.04, 5.68] <0.001 4.60 [3.81, 5.48] 4.91 [4.17, 5.80] <0.001
SUA (mmol/L, median (IQR)) 319.40 [258.20, 383.00] 291.80 [237.10, 352.00] 359.60 [303.10, 418.40] <0.001 303.00 [249.00, 355.00] 465.60 [440.70, 504.00] <0.001
SCR (umol/L, median (IQR)) 72.00 [60.00, 83.00] 69.00 [57.40, 80.50] 75.20 [65.00, 86.00] <0.001 70.00 [58.50, 81.00] 82.00 [73.00, 92.00] <0.001
SBP (mmHg, median (IQR)) 122.00 [110.00, 135.00] 119.00 [109.00, 130.00] 130.00 [119.00, 140.00] <0.001 120.00 [110.00, 134.00] 128.00 [118.00, 140.00] <0.001
DBP (mmHg, median (IQR)) 77.00 [70.00, 85.00] 73.00 [67.00, 80.00] 81.00 [74.00, 90.00] <0.001 76.00 [69.00, 84.00] 80.00 [73.00, 90.00] <0.001
BMI≥23, n(%) 1117303 (70.36) 509863 (53.56) 607440 (95.51) <0.001 922215 (67.36) 195088 (89.16) <0.001
Hypertension, n(%) 432501 (27.33) 176297 (18.58) 256204 (40.44) <0.001 349293 (25.60) 83208 (38.16) <0.001
Diabetes, n(%) 120285 (7.57) 38503 (4.04) 81782 (12.86) <0.001 104992 (7.67) 15293 (6.99) <0.001
Hyperuricemia, n(%) 218796 (13.78) 74160 (7.79) 144636 (22.74) <0.001
MAFLD, n(%) 635977 (40.05) 491341 (35.89) 144636 (66.11) <0.001

FBG, fasting blood glucose; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TC, total cholesterol; TG, triglycerides; WC, waist circumference; BMI, body mass index; ALT, alanine aminotransferase; AST, aspartate transaminase; BUN, blood urea nitrogen; SUA, serum uric acid; SCR, serum creatinine; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAFLD, metabolic dysfunction-associated fatty liver disease.

*: P-value was calculated by Kruskal-Wallis test for continuous variables, as well as the χ2 test or Fisher’s exact test for categorical variables.